Logo

Dakota Technologies Wins $750K SBIR Grant for High-Throughput Screening

Sep 10, 2004

NEW YORK, Sept. 10 (GenomeWeb News) - Dakota Technologies has received a $750,000 grant from the US National Institutes of Health to develop a multi-mode microplate reader and high-throughput screening assays based on the firm's fluorescence measurement technology, Dakota said recently.

 

Dakota, based in Fargo, ND, claims that by combining microchip laser sources with its transient digitizer, they can generate high quality fluorescence lifetime data, including time-resolved polarization, "much faster and at substantially lower cost than alternative approaches."

 

Dakota said the Phase II Small Business Innovation Research grant will help it "accelerate ... plans" to commercialize products for high-throughput and high-content screening in drug discovery.

 

The assays Dakota is developing "aim to overcome false positives caused by fluorescence interferences commonly encountered in high-throughput screening," the company said in a statement. Its lifetime measurement technique, which Dakota said "provides enhanced multiplexing capabilities," will also be used to develop assays that are suited to multi-parameter analysis.

Breaking News
The Scan

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.

Mitochondrial Replacement Therapy Embryos Appear Largely Normal in Single-Cell 'Omics Analyses

Embryos produced with spindle transfer-based mitochondrial replacement had delayed demethylation, but typical aneuploidy and transcriptome features in a PLOS Biology study.

Cancer Patients Report Quality of Life Benefits for Immune Checkpoint Inhibitors

Immune checkpoint inhibitor immunotherapy was linked in JAMA Network Open to enhanced quality of life compared to other treatment types in cancer patients.

Researchers Compare WGS, Exome Sequencing-Based Mendelian Disease Diagnosis

Investigators find a diagnostic edge for whole-genome sequencing, while highlighting the cost advantages and improving diagnostic rate of exome sequencing in EJHG.